DOCSLIB.ORG

Controlled Substances for Use in Toyota Motor Corporation and Ford Disclosing All Changes in Membership

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Controlled Substances for Use in Toyota Motor Corporation and Ford Disclosing All Changes in Membership 78044 Federal Register / Vol. 76, No. 241 / Thursday, December 15, 2011 / Notices 15 U.S.C. 4301 et seq. (‘‘the Act’’), to file additional written notifications controlled substances for use in Toyota Motor Corporation and Ford disclosing all changes in membership. industrial processes. Motor Company Collaboration (‘‘Toyota On February 10, 1986, PERF filed its On October 21, 2011, a notice entitled and Ford’’) has filed written original notification pursuant to Section ‘‘Controlled Substances: Proposed notifications simultaneously with the 6(a) of the Act. The Department of Aggregate Production Quotas for 2012’’ Attorney General and the Federal Trade Justice published a notice in the Federal was published in the Federal Register Commission disclosing (1) The Register pursuant to Section 6(b) of the (76 FR 65537). That notice proposed the identities of the parties to the venture Act on March 14, 1986 (51 FR 8903). 2012 aggregate production quotas for and (2) the nature and objectives of the The last notification was filed with each basic class of controlled substance venture. The notifications were filed for the Department on June 2, 2010. A listed in Schedules I and II. All the purpose of invoking the Act’s notice was published in the Federal interested persons were invited to provisions limiting the recovery of Register pursuant to Section 6(b) of the comment on or object to the proposed antitrust plaintiffs to actual damages Act on August 2, 2010 (75 FR 45156). aggregate production quotas on or before under specified circumstances. November 21, 2011. Patricia A. Brink, Pursuant to Section 6(b) of the Act, Sixteen responses (eleven from DEA Director of Civil Enforcement, Antitrust registered manufacturers, and five from the identities of the parties to the Division. venture are: Toyota Motor Corporation, other members of the public) were [FR Doc. 2011–32114 Filed 12–14–11; 8:45 am] Toyota City, JAPAN; and Ford Motor received within the published comment Company, Dearborn, MI. BILLING CODE P period, offering comments on a total of 37 Schedule I and II controlled The general area of Toyota and Ford’s substances. Several comments discussed planned activity is the research and DEPARTMENT OF JUSTICE the national prescription drug abuse development of (a) A hybrid system epidemic and urged DEA to reduce initially targeted for use in sport utility Drug Enforcement Administration quotas for prescription painkillers and vehicles and light trucks, and (b) [Docket No. DEA 358E] opioids. Addressing prescription drug standards and/or enabling technologies abuse requires a multi-faceted approach for vehicle telematics. The parties may which includes education, treatment, subsequently agree to expand the scope Controlled Substances: Established Aggregate Production Quotas for 2012 and enforcement. of the collaboration to include The quota system is specifically production. AGENCY: Drug Enforcement designed to operate within the statutory Patricia A. Brink, Administration (DEA), Department of framework of the CSA, in conjunction Director of Civil Enforcement, Antitrust Justice. with other controls to enable DEA to Division. ACTION: Notice. monitor the movement of controlled [FR Doc. 2011–32113 Filed 12–14–11; 8:45 am] substances and certain chemicals into SUMMARY: This notice establishes the and through the closed system of BILLING CODE P initial 2012 aggregate production quotas distribution to help prevent diversion of for controlled substances in Schedules I such substances into the illicit market. DEPARTMENT OF JUSTICE and II of the Controlled Substances Act Through the quota system, DEA limits (CSA). the amount of those substances and Antitrust Division DATES: Effective Date: December 15, chemicals manufactured each year to 2011. those quantities that will provide for the Notice Pursuant to the National estimated medical, scientific, research, Cooperative Research and Production FOR FURTHER INFORMATION CONTACT: John and industrial needs, lawful export Act of 1993—Petroleum Environmental W. Partridge, Office of Diversion requirements, and the establishment Research Forum Control, Drug Enforcement and maintenance of reserve stocks for Administration, 8701 Morrissette Drive, the United States. All aspects of the Notice is hereby given that, on Springfield, VA 22152, Telephone: (202) closed system of distribution must work November 1, 2011, pursuant to Section 307–4654. together to reduce or eliminate the 6(a) of the National Cooperative SUPPLEMENTARY INFORMATION: Section diversion of controlled substances. Research and Production Act of 1993, 306 of the Controlled Substances Act Other commenters stated that the 15 U.S.C. 4301 et seq. (‘‘the Act’’), (CSA) (21 U.S.C. 826) requires that the proposed aggregate production quotas Petroleum Environmental Research Attorney General establish aggregate for alfentanil, amphetamine (for sale), Forum (‘‘PERF’’) has filed written production quotas for each basic class of codeine (for conversion), codeine (for notifications simultaneously with the controlled substance listed in Schedules sale), dihydrocodeine, Attorney General and the Federal Trade I and II. This responsibility has been dihydromorphine, diphenoxylate, Commission disclosing changes in its delegated to the Administrator of the hydrocodone (for sale), membership. The notifications were DEA by 28 CFR 0.100. hydromorphinol, levorphanol, filed for the purpose of extending the The 2012 aggregate production quotas lisdexamfetamine, meperidine, Act’s provisions limiting the recovery of represent those quantities of Schedule I meperidine intermediate A, meperidine antitrust plaintiffs to actual damages and II controlled substances that may be intermediate B, meperidine under specified circumstances. produced in the United States in 2012 intermediate C, methadone, methadone Specifically, Nalco Environmental to provide adequate supplies of each intermediate, methamphetamine, Solutions, LLC, Sugarland, TX, has been substance for the estimated medical, methylphenidate, morphine (for added as a party to this venture. scientific, research, and industrial needs conversion), morphine (for sale), No other changes have been made in of the United States, lawful export morphine-N-oxide, nabilone, either the membership or planned requirements, and the establishment noroxymorphone (for conversion), activity of the group research project. and maintenance of reserve stocks. 21 noroxymorphone (for sale), opium Membership in this group research U.S.C. 826(a) and 21 CFR 1303.11. (tincture), oripavine, oxycodone (for project remains open, and PERF intends These quotas do not include imports of conversion), oxycodone (for sale), VerDate Mar<15>2010 16:49 Dec 14, 2011 Jkt 226001 PO 00000 Frm 00082 Fmt 4703 Sfmt 4703 E:\FR\FM\15DEN1.SGM 15DEN1 mstockstill on DSK4VPTVN1PROD with NOTICES Federal Register / Vol. 76, No. 241 / Thursday, December 15, 2011 / Notices 78045 oxymorphone (for conversion), nabilone, pentobarbital, phenylacetone, Regarding amphetamine (for sale), oxymorphone (for sale), pentobarbital, properidine, and tapentadol are codeine (for conversion), codeine (for phenylacetone, properidine, sufentanil, warranted. This notice reflects those sale), dihydromorphine, hydrocodone tapentadol, and thebaine were adjustments. (for sale), levorphanol, methadone, insufficient to provide for the estimated When DEA published the Proposed methadone intermediate, medical, scientific, research, and Aggregate Production Quotas for 2012 methamphetamine, methylphenidate, industrial needs of the United States, on October 21, 2011, that notice morphine (for conversion), morphine export requirements, and the proposed that all Schedule I and II (for sale), noroxymorphone (for establishment and maintenance of controlled substances included in 21 conversion), noroxymorphone (for sale), reserve stocks. opium (tincture), oripavine, oxycodone In determining the aggregate CFR 1308.11 and 1308.21 but not production quotas, DEA has taken into specifically referenced in that notice be (for conversion), oxycodone (for sale), consideration the above comments established at zero. That reference oxymorphone (for conversion), along with the factors set forth at 21 extended to the three synthetic oxymorphone (for sale), sufentanil, and CFR 1303.11(b), in accordance with 21 cathinones (4-methyl-N- thebaine, DEA has determined that the U.S.C. 826(a) and other relevant factors, methylcathinone; 3,4-methylenedioxy- proposed initial 2012 aggregate including the consideration of 2011 N-methylcathinone; and production quotas are sufficient to meet manufacturing quotas, current 2011 3,4,methylenedioxypyrovalerone) that the current 2012 estimated medical, sales and inventories, 2012 export were temporarily placed in Schedule I scientific, research, and industrial needs requirements, additional applications pursuant to the final order also of the United States. This notice for quotas, as well as information on published on October 21, 2011, at 76 FR finalizes these aggregate production research and product development 65371. No comments were received quotas at the same amounts as requirements. Based on this within the published comment period proposed. information, DEA determined that regarding the proposed quota for the In accordance with 21 U.S.C. 826 and adjustments to the proposed aggregate three synthetic cathinones, however, 21 CFR 1303.11, the Administrator production quotas for alfentanil, DEA has determined, based on the dihydrocodeine, diphenoxylate, information described above, that an
Load more

Recommended publications
  • Minnesota Statutes 1979 Supplement
    MINNESOTA STATUTES 1979 SUPPLEMENT 152.01 PROHIBITED DRUGS CHAPTER 152. PROHIBITED DRUGS Sec. 152.01 Definitions. 152.02 Schedules of controlled substances; admin­ istration of chapter. 152.01 Definitions. [For text of subds 1 to 8, see M.S.1978] Subd. 9. Marijuana. "Marijuana" means all parts of the plant of any species of the genus Cannabis, including all agronomical varieties, whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin, but shall not include the mature stalks of such plant, fiber from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mix­ ture, or preparation of such mature stalks, except the resin extracted therefrom, fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination. [For text of subds 10 to 17, see M.S.1978] [ 1979 c 157 s 1 ] 152.02 Schedules of controlled substances; administration of chapter. [For text of subd 1, see M.S.1978) Subd. 2. The following items are listed in Schedule I: (1) Any of the following substances, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the exis­ tence of such isomers, esters, ethers and salts is possible within the specific chemical des­ ignation: Acetylmethadol; Allylprodine; Alphacetylmethadol; Alphameprodine; Alpham- ethadol; Benzethidine; Betacetylmethadol; Betameprodine; Betamethadol; Betaprodine; Clonitazene; Dextromoramide; Dextrorphan; Diampromide; Diethyliambutene; Dime- noxadol; Dimepheptanol; Dimethyliambutene; Dioxaphetyl butyrate; Dipipanone; Ethylmethylthiambutene; Etonitazene; Etoxeridine; Furethidine; Hydroxypethidine; Ke- tobemidone; Levomoramide; Levophenacylmorphan; Morpheridine; Noracymethadol; Norlevorphanol; Normethadone; Norpipanone; Phenadoxone; Phenampromide; Pheno- morphan; Phenoperidine; Piritramide; Proheptazine; Properidine; Racemoramide; Tri­ meperidine.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • SENATE BILL No. 259 No
    SENATE BILL No. 259 SENATE BILL No. 259 March 10, 2011, Introduced by Senators JONES, CASPERSON and SCHUITMAKER and referred to the Committee on Judiciary. A bill to amend 1978 PA 368, entitled "Public health code," by amending section 7212 (MCL 333.7212), as amended by 2010 PA 171. THE PEOPLE OF THE STATE OF MICHIGAN ENACT: 1 Sec. 7212. (1) The following controlled substances are 2 included in schedule 1: 3 (a) Any of the following opiates, including their isomers, 4 esters, the ethers, salts, and salts of isomers, esters, and 5 ethers, unless specifically excepted, when the existence of these 6 isomers, esters, ethers, and salts is possible within the 7 specific chemical designation: SENATE BILL No. 259 00981'11 TLG 2 1 Acetylmethadol Difenoxin Noracymethadol 2 Allylprodine Dimenoxadol Norlevorphanol 3 Alpha-acetylmethadol Dimepheptanol Normethadone 4 Alphameprodine Dimethylthiambutene Norpipanone 5 Alphamethadol Dioxaphetyl butyrate Phenadoxone 6 Benzethidine Dipipanone Phenampromide 7 Betacetylmethadol Ethylmethylthiambutene Phenomorphan 8 Betameprodine Etonitazene Phenoperidine 9 Betamethadol Etoxeridine Piritramide 10 Betaprodine Furethidine Proheptazine 11 Clonitazene Hydroxypethidine Properidine 12 Dextromoramide Ketobemidone Propiram 13 Diampromide Levomoramide Racemoramide 14 Diethylthiambutene Levophenacylmorphan Trimeperidine 15 Morpheridine 16 (b) Any of the following opium derivatives, their salts, 17 isomers, and salts of isomers, unless specifically excepted, when 18 the existence of these salts, isomers, and salts of
    [Show full text]
  • 2020 Kansas Statutes
    2020 Kansas Statutes 65-4105. Substances included in schedule I. (a) The controlled substances listed in this section are included in schedule I and the number set forth opposite each drug or substance is the DEA controlled substances code that has been assigned to it. (b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation: (1) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- phenylacetamide) 9821 (2) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide) 9815 (3) Acetylmethadol 9601 (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide; acryloylfentanyl) 9811 (5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide) 9551 (6) Allylprodine 9602 (7) Alphacetylmethadol 9603(except levo-alphacetylmethadol also known as levo- alpha-acetylmethadol, levomethadyl acetate or LAAM) (8) Alphameprodine 9604 (9) Alphamethadol 9605 (10) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine) 9814 (11) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N- phenylpropanamide) 9832 (12) Benzethidine 9606 (13) Betacetylmethadol 9607 (14) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N- phenylpropanamide) 9830 (15) Beta-hydroxy-3-methylfentanyl (other
    [Show full text]
  • Information to Users
    The direct and modulatory antinociceptive actions of endogenous and exogenous opioid delta agonists Item Type text; Dissertation-Reproduction (electronic) Authors Vanderah, Todd William. Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 04/10/2021 00:14:57 Link to Item http://hdl.handle.net/10150/187190 INFORMATION TO USERS This ~uscript }las been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely. event that the author did not send UMI a complete mannscript and there are missing pages, these will be noted Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginnjng at the upper left-hand comer and contimJing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy.
    [Show full text]
  • CONTROLLED SUBSTANCE, DRUG, DEVICE and COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun
    CONTROLLED SUBSTANCE, DRUG, DEVICE AND COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun. 23, 2011, P.L. 36, No. 7 Cl. 35 Session of 2011 No. 2011-7 SB 1006 AN ACT Amending the act of April 14, 1972 (P.L.233, No.64), entitled "An act relating to the manufacture, sale and possession of controlled substances, other drugs, devices and cosmetics; conferring powers on the courts and the secretary and Department of Health, and a newly created Pennsylvania Drug, Device and Cosmetic Board; establishing schedules of controlled substances; providing penalties; requiring registration of persons engaged in the drug trade and for the revocation or suspension of certain licenses and registrations; and repealing an act," further providing for Schedule I controlled substances. The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows: Section 1. Section 4(1) of the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, amended November 24, 1999 (P.L.894, No.55), is amended to read: Section 4. Schedules of Controlled Substances.--The following schedules include the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated. (1) Schedule I--In determining that a substance comes within this schedule, the secretary shall find: a high potential for abuse, no currently accepted medical use in the United States, and a lack of accepted safety for use under medical supervision. The following controlled substances are included in this schedule: (i) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation: 1.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Drugs of Abuseon September Archived 13-10048 No
    U.S. DEPARTMENT OF JUSTICE DRUG ENFORCEMENT ADMINISTRATION WWW.DEA.GOV 9, 2014 on September archived 13-10048 No. v. Stewart, in U.S. cited Drugs of2011 Abuse EDITION A DEA RESOURCE GUIDE V. Narcotics WHAT ARE NARCOTICS? Also known as “opioids,” the term "narcotic" comes from the Greek word for “stupor” and originally referred to a variety of substances that dulled the senses and relieved pain. Though some people still refer to all drugs as “narcot- ics,” today “narcotic” refers to opium, opium derivatives, and their semi-synthetic substitutes. A more current term for these drugs, with less uncertainty regarding its meaning, is “opioid.” Examples include the illicit drug heroin and pharmaceutical drugs like OxyContin®, Vicodin®, codeine, morphine, methadone and fentanyl. WHAT IS THEIR ORIGIN? The poppy papaver somniferum is the source for all natural opioids, whereas synthetic opioids are made entirely in a lab and include meperidine, fentanyl, and methadone. Semi-synthetic opioids are synthesized from naturally occurring opium products, such as morphine and codeine, and include heroin, oxycodone, hydrocodone, and hydromorphone. Teens can obtain narcotics from friends, family members, medicine cabinets, pharmacies, nursing 2014 homes, hospitals, hospices, doctors, and the Internet. 9, on September archived 13-10048 No. v. Stewart, in U.S. cited What are common street names? Street names for various narcotics/opioids include: ➔ Hillbilly Heroin, Lean or Purple Drank, OC, Ox, Oxy, Oxycotton, Sippin Syrup What are their forms? Narcotics/opioids come in various forms including: ➔ T ablets, capsules, skin patches, powder, chunks in varying colors (from white to shades of brown and black), liquid form for oral use and injection, syrups, suppositories, lollipops How are they abused? ➔ Narcotics/opioids can be swallowed, smoked, sniffed, or injected.
    [Show full text]
  • SB566 1 119787-1 2 by Senators Orr, Erwin, Sanford, and Butler 3 RFD
    1 SB566 2 119787-1 3 By Senators Orr, Erwin, Sanford, and Butler 4 RFD: Judiciary 5 First Read: 23-MAR-10 Page 0 1 119787-1:n:03/08/2010:DA/mfp LRS2010-1714 2 3 4 5 6 7 8 SYNOPSIS: Under existing law, salvia divinorum and 9 Salvinorin A are not listed as controlled 10 substances. 11 This bill would list salvia divinorum and 12 Salvinorin A as Schedule I controlled substances. 13 14 A BILL 15 TO BE ENTITLED 16 AN ACT 17 18 To amend Section 20-2-23 of the Code of Alabama 19 1975, relating to Schedule I controlled substances, to list 20 salvia divinorum and Salvinorin A. 21 BE IT ENACTED BY THE LEGISLATURE OF ALABAMA: 22 Section 1. Section 20-2-23 of the Code of Alabama 23 1975, is amended to read as follows: 24 "§20-2-23. 25 "The controlled substances listed in this section 26 are included in Schedule I: Page 1 1 "(1) Any of the following opiates, including their 2 isomers, esters, ethers, salts, and salts of isomers, esters 3 and ethers, unless specifically excepted, whenever the 4 existence of these isomers, esters, ethers and salts is 5 possible within the specific chemical designation: 6 "a. Acetylmethadol; 7 "b. Allylprodine; 8 "c. Alphacetylmethadol; 9 "d. Alphameprodine; 10 "e. Alphamethadol; 11 "f. Benzethidine; 12 "g. Betacetylmethadol; 13 "h. Betameprodine; 14 "i. Betamethadol; 15 "j. Betaprodine; 16 "k. Clonitazene; 17 "l. Dextromoramide; 18 "m. Dextrorphan; 19 "n. Diampromide; 20 "o. Diethylthiambutene; 21 "p. Dimenoxadol; 22 "q. Dimepheptanol; 23 "r.
    [Show full text]
  • Removing Samidorphan from Schedule II
    The Acting Administrator of the Drug Enforcement Administration issued an order to extend the temporary schedule I status of ethyl 2-(1-(5- fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (Other name: 5F-EDMB-PINACA); methyl 2-(1-(5-fluoropentyl)-1H-indole-3- carboxamido)-3,3-dimethylbutanoate (Other name: 5F-MDMB-PICA); N- (adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (Other names: FUB-AKB48, FUB-APINACA, AKB48, N-(4-fluorobenzyl)); 1-(5- fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole- 3-carboxamide (Others names: 5F-CUMYL-PINACA; SGT-25); and (1-(4- fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (Other name: FUB-144), and their optical, positional, and geometric isomers, salts, and salts of isomers. This order will extend the temporary scheduling of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL- PINACA and FUB-144 for one year or until the permanent scheduling action for these substances is completed, whichever occurs first. This order was published in the March 31, 2021 issue of the Federal Register, Volume 86, Number 60, pages 16669-16670 and was effective April 16, 2021. The Acting Administrator of the Drug Enforcement Administration issued a final rule removing samidorphan (3-carboxamido-4-hydroxy naltrexone) and its salts from the schedules of the Controlled Substances Act. This final rule was published in the April 19, 2021 issue of the Federal Register, Volume 86, Number 73, pages 20284-20286 and was effective April 19, 2021. This action was based upon the following: 1. Samidorphan does not possess abuse or dependence potential, 2.
    [Show full text]
  • Federal Register/Vol. 85, No. 205/Thursday, October 22, 2020
    67374 Federal Register / Vol. 85, No. 205 / Thursday, October 22, 2020 / Notices incorporating the same, and any Hisense International (Hong Kong) Responses to the complaint and the associated hardware, software, and/or America Investment Co., Ltd., Room notice of investigation must be firmware enabling digital video 3101–3105, Singga Commercial submitted by the named respondents in capabilities; (b) digital video-capable Centre, No. 148 Connaught Road accordance with section 210.13 of the displays containing such components; West, Sheung Wan, Hong Kong (SAR) Commission’s Rules of Practice and and (c) digital video-capable computers HP, Inc., 1501 Page Mill Rd., Palo Alto, Procedure, 19 CFR 210.13. Pursuant to containing such components’’; CA 94304–1126 19 CFR 201.16(e) and 210.13(a), as (3) Pursuant to Commission Rule Lenovo Group Ltd., Lincoln House, 23rd amended in 85 FR 15798 (March 19, 210.50(b)(1), 19 CFR 210.50(b)(1), the Floor, Taikoo Place, 979 King’s Road, 2020), such responses will be presiding administrative law judge shall Quarry Bay, Hong Kong (SAR) considered by the Commission if take evidence or other information and Lenovo (United States), Inc., 8001 received not later than 20 days after the hear arguments from the parties and Development Drive, Morrisville, NC date of service by the complainant of the other interested persons with respect to 27560 complaint and the notice of the public interest in this investigation, LG Electronics, Inc., LG Twin Towers, investigation. Extensions of time for as appropriate, and provide the 128, Yeoui-daero, Yeongdeungpo-gu, submitting responses to the complaint Commission with findings of fact and a Seoul, Republic of Korea, 07736 and the notice of investigation will not recommended determination on this LG Electronics USA, Inc., 1000 Sylvan be granted unless good cause therefor is issue, which shall be limited to the Avenue, Englewood Cliffs, NJ 07632 shown.
    [Show full text]
  • Chapter 329 [New] Uniform Controlled Substances Act
    CHAPTER 329 [NEW] UNIFORM CONTROLLED SUBSTANCES ACT Part I. General Provisions Section 329-1 Definitions 329-2 Hawaii advisory commission on drug abuse and controlled substances; number; appointment 329-3 Annual report 329-4 Duties of the commission Part II. Standards and Schedules 329-11 Authority to schedule controlled substances 329-12 Nomenclature 329-13 Schedule I tests 329-14 Schedule I 329-15 Schedule II tests 329-16 Schedule II 329-17 Schedule III Tests 329-18 Schedule III 329-19 Schedule IV tests 329-20 Schedule IV 329-21 Schedule V tests 329-22 Schedule V 329-23 Republishing and distribution of schedules Part III. Regulation of Manufacture, Distribution, Prescription, and Dispensing of Controlled Substances 329-31 Rules 329-31.5 Clinics 329-32 Registration requirements 329-33 Registration 329-34 Revocation and suspension of registration 329-35 Order to show cause 329-36 Records of registrants 329-37 Filing requirements 329-38 Prescriptions 329-39 Labels 329-40 Methadone treatment programs Part IV. Offenses and Penalties 329-41 Prohibited acts B-penalties 329-42 Prohibited acts C-penalties 329-43 Penalties under other laws 329-43.5 Prohibited acts related to drug paraphernalia Amended 0612 1 329-44 Notice of conviction to be sent to licensing board, department of commerce and consumer affairs 329-45 Repealed 329-46 Prohibited acts related to visits to more than one practitioner to obtain controlled substance prescriptions 329-49 Administrative penalties 329-50 Injunctive relief Part V. Enforcement and Administrative Provisions 329-51 Powers of enforcement personnel 329-52 Administrative inspections 329-53 Injunctions 329-54 Cooperative arrangements and confidentiality 329-55 Forfeitures 329-56 Burden of proof; liabilities 329-57 Judicial review 329-58 Education and research 329-59 Controlled substance registration revolving fund; established Part VI.
    [Show full text]